Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study (NCT07298408) | Clinical Trial Compass
RecruitingPhase 1/2
Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study
United States20 participantsStarted 2026-04-02
Plain-language summary
The "Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot study (CBD-DPN1)" is a double-blinded, placebo-controlled, crossover pilot study evaluating the efficacy of Cannabidiol (CBD) and full-spectrum CBD (fsCBD) tinctures in treating Diabetic Peripheral Neuropathy (DPN)-associated pain. DPN is a common, highly distressing complication of diabetes, characterized by chronic pain and loss of sensory function, for which currently available treatments primarily offer only symptomatic relief. CBD and fsCBD are being investigated for their potential neuroprotective and analgesic effects by regulating inflammation and oxidative stress.
The study aims to recruit 12 to 20 adult participants who have mild to moderate DPN. Subjects will receive either an active treatment (CBD isolate or fsCBD in MCT oil, dosed at 50 mg twice daily for a total of 100 mg daily) or a placebo during two sequential 6-week phases. The overall objective of this pilot phase is primarily methodological: to test and refine the clinical protocol, assess patient compliance and acceptability of the CBD formulations, and generate sufficient data to calculate the necessary sample size for a larger, definitive study. Efficacy will be measured using objective and subjective metrics, including DPN severity (DN4 Assessment Tool and DPNCheckâ„¢ for nerve conduction velocity) and pain level (PainDetect Questionnaire). Secondary outcomes include evaluating mood (HADS), sleep quality (MOS Sleep Scale), and quality of life (EQ-5D-5L).
Who can participate
Age range40 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Adult aged 40 to 70 years
✓. Diagnosis of Type 2 Diabetes
✓. Ambulatory and independently living adult
✓. Minimum body weight of 50 kg (to ensure daily dose ≤2 mg/kg)
✓. Physical exam completed within the previous 6 months
✓. Liver Function Studies (ALT and AST) completed within the previous six months showing normal values
✓. If NAFLD is present, ALT and AST levels are ≤2 times the Upper Limit of Normal (ULN)
✓. DN4 questionnaire results indicate mild to moderate DPN
Exclusion criteria
✕. High-risk or severely ill individuals (e.g., high risk for general anesthesia, significant limitations due to heart/lung disease, ascites, renal failure, loss of limbs from diabetic complications)
✕. Uncontrolled or severe cardiovascular disease (e.g., unstable angina, uncontrolled heart failure, recent myocardial infarction)
What they're measuring
1
DPN Pain Level
Timeframe: Baseline (Day 0), Day 7, Day 21 (at home by subject), Day 35 (at home by subject), End of Phase I (Day 49), Day 63 (at home by subject), Day 77 (at home by subject), End of Phase II (Day 105).
2
Diabetic peripheral neuropathy diagnosis
Timeframe: Baseline Screening (Day 0)
3
Diabetic Neuropathy Severity
Timeframe: Baseline, End of Phase I (Day 49) (for NCT), End of Phase II (Day 91) (for NCT).
✕. History of atrial fibrillation, dysrhythmias, MI within the previous 2 years, or stroke
✕. Severe respiratory illness (e.g., uncontrolled asthma, COPD with frequent exacerbations, oxygen dependence)
✕. Severe or uncontrolled liver disease (e.g., cirrhosis, active viral hepatitis A, B, or C, autoimmune hepatitis, uncontrolled primary biliary cholangitis or primary sclerosing cholangitis)
✕. Elevation of liver enzymes (ALT or AST) exceeding 2 times the ULN, or bilirubin exceeding the ULN
✕. Severe or uncontrolled kidney disease (e.g., end-stage renal disease requiring dialysis, uncontrolled nephrotic syndrome)
✕. History of malignancy within the past 5 years (excluding certain low-risk non-melanoma skin cancers)